Novel T-cell signalling and cellular pathways in immunotherapy

Version imprimable
February 27, 2018
Christopher Rudd

On March 2nd, 2018, the CRCHUM Conferences invites professor Christopher E. Rudd, researcher at the Maisonneuve-Rosemont Hospital Research Centre. 

His laboratory has an interest in the receptors and the signaling pathways in T-cells that regulate adaptive immunity and cancer immunotherapy. T-cell activation is induced by signals from the antigen-receptor (TCR) as well as positive and negative signals from co-receptors CD28, CTLA-4 and PD-1. They recently have uncovered novel T-cell signaling pathways that regulate p21ras, transport across the nuclear pore complex (NPC) and pathways that control the expression of the inhibitory co-receptors CTLA-4 and PD-1 on T-cells. These mechanisms that underlie the activation of these regulatory pathways will be discussed as well as their application for improved cancer immunotherapy.

Guest of John Stagg, theme: cancer. 

This conference will be presented in English.

Friday, march 2nd, 2018, at noon
Auditorium of the CRCHUM, R05.210 and R05.220
900 Saint-Denis Street, 5th floor 
Montreal (Quebec)  H2X 0A9

Christopher E. Rudd, Ph.D., D.Sc., FRCPath
Researcher, Maisonneuve-Rosemont Hospital Research Centre
Full Professor, Université de Montréal


About CRCHUM Conferences

The CRCHUM Conferences are free weekly meetings featuring renowned scientific speakers from various disciplines. These conferences are accredited by the Royal College of Physicians and Surgeons of Canada as continuing professional development activities. The CRCHUM conferences are made possible thanks to the financial support of our partners: AstraZeneca, Banque Nationale, Biron, Charles River, GSK Canada, Lilly, Médicaments novateurs Canada, Merck, Pfizer, Québecor, Roche & Servier.

About our scientific activities

Schedule of scientific activities at the CRCHUM